1. GPCR/G Protein
  2. Glucagon Receptor

Lixisenatide 

Cat. No.: HY-P0119 Purity: 98.36%
Data Sheet SDS Handling Instructions

Lixisenatide inhibit glucagon release, markedly reduce postprandial glucago. have a promoting effct in diabetes mellitus (T2DM).

For research use only. We do not sell to patients.
Lixisenatide Chemical Structure

Lixisenatide Chemical Structure

CAS No. : 320367-13-3

Size Price Stock Quantity
10 mM * 1 mL in Water $5291 In-stock
1 mg $220 In-stock
5 mg $660 In-stock
10 mg $990 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • Biological Activity

  • Technical Information

  • Purity & Documentation

  • References

Description

Lixisenatide inhibit glucagon release, markedly reduce postprandial glucago. have a promoting effct in diabetes mellitus (T2DM).

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02020629 Lund University Type 2 Diabetes December 2013 Phase 4
NCT02049034 University of Surrey|Sanofi Type 2 Diabetes January 2014 Phase 4
NCT02767596 Laniado Hospital Diabetes Mellitus Type 2 July 12, 2016 Phase 4
NCT02640118 University Hospital, Gentofte, Copenhagen|MCM Vaccines B.V. Diabetes After Total Pancreatectomy August 2015
NCT01146678 Sanofi Type 1 Diabetes Mellitus June 2010 Phase 1
NCT01147250 Sanofi Acute Coronary Syndrome June 2010 Phase 3
NCT02308254 Royal Adelaide Hospital|Sanofi|National Health and Medical Research Council, Australia Diabetes Mellitus|Gastroparesis November 2013 Phase 1|Phase 2
NCT01960179 Sanofi Type 2 Diabetes Mellitus November 2013 Phase 3
NCT02276196 VU University Medical Center Diabetic Kidney Disease|Diabetic Nephropathy|Diabetes Mellitus|Glucagon-Like Peptide 1 September 2014 Phase 4
NCT01798706 Sanofi Type 2 Diabetes June 2013 Phase 3
NCT02168491 Medical University of Vienna Type 2 Diabetes Mellitus November 2014 Phase 3
NCT02274740 Sanofi Type II Diabetes Mellitus April 2015 Phase 2
NCT02058147 Sanofi Type 2 Diabetes February 2014 Phase 3
NCT02941367 Sanofi Diabetes Mellitus, Type 2 February 23, 2017 Phase 4
NCT01632163 Sanofi Type 2 Diabetes Mellitus October 2012 Phase 3
NCT02231658 Profil Institut für Stoffwechselforschung GmbH Diabetes Mellitus July 16, 2015 Phase 1
NCT02803918 Sanofi Type 2 Diabetes Mellitus May 17, 2017 Phase 1
NCT02749890 Sanofi Type 2 Diabetes Mellitus May 2016 Phase 3
NCT01476475 Sanofi Type 2 Diabetes Mellitus November 2011 Phase 2
NCT01517412 Sanofi Type 2 Diabetes Mellitus February 2012 Phase 3
NCT00905255 Sanofi Diabetes Mellitus, Type 2 May 2009 Phase 3
NCT00931372 Sanofi|Profil GmbH, Neuss, Germany Diabetes Mellitus, Type 2 June 2009 Phase 1
NCT01973231 Novo Nordisk A/S Diabetes|Diabetes Mellitus, Type 2 October 2013 Phase 4
NCT01572649 Sanofi Type 2 Diabetes Mellitus May 2012 Phase 1
NCT01175473 Sanofi Type 2 Diabetes Mellitus August 2010 Phase 2
NCT01169779 Sanofi Type 2 Diabetes Mellitus July 2010 Phase 3
NCT02058160 Sanofi Type 2 Diabetes January 2014 Phase 3
NCT00975286 Sanofi Type 2 Diabetes Mellitus October 2009 Phase 3
NCT01768559 Sanofi Type 2 Diabetes January 2013 Phase 3
NCT02787551 Sanofi Type 2 Diabetes Mellitus July 6, 2016 Phase 3
NCT01940965 Sanofi Type 2 Diabetes Mellitus September 2013 Phase 3
NCT01596504 Sanofi Type 2 Diabetes Mellitus May 2012 Phase 2
NCT00976937 Sanofi Type 2 Diabetes Mellitus August 2009 Phase 3
NCT02713477 Sanofi Type 2 Diabetes Mellitus April 2016 Phase 1
NCT00763815 Sanofi Diabetes Mellitus Type 2 September 2008 Phase 3
NCT00715624 Sanofi Diabetes Mellitus, Type 2 July 2008 Phase 3
NCT00713830 Sanofi Diabetes Mellitus, Type 2 July 2008 Phase 3
NCT00707031 Sanofi Diabetes Mellitus, Type 2 June 2008 Phase 3
NCT00688701 Sanofi Diabetes Mellitus, Type 2 May 2008 Phase 3
NCT00866658 Sanofi Diabetes Mellitus, Type 2 March 2009 Phase 3
NCT02200991 Sanofi Type 2 Diabetes Mellitus August 2014 Phase 4
NCT00763451 Sanofi Diabetes Mellitus, Type 2 September 2008 Phase 3
NCT00712673 Sanofi Diabetes Mellitus, Type 2 June 2008 Phase 3
NCT00299871 Sanofi Type 2 Diabetes February 2006 Phase 2
NCT02752828 Sanofi Type 2 Diabetes Mellitus May 2016 Phase 3
NCT02745470 Seoul National University Hospital|Seoul National University Diabetes Mellitus February 2016
NCT02752412 Sanofi Type 2 Diabetes Mellitus May 17, 2016 Phase 3
View MoreCollapse
References
M.Wt

4858.49

Formula

C₂₁₅H₃₄₇N₆₁O₆₅S

CAS No.

320367-13-3

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

H2O

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Lixisenatide
Cat. No.:
HY-P0119
Quantity: